Sanofi (France)

2055 articles with Sanofi (France)

• Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis 

  3/21/2023

  The European Commission has approved Dupixent® in the European Union to treat severe atopic dermatitis in children aged 6 months to 5 years old who are candidates for systemic therapy.

• Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis

  3/21/2023

  Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission has approved Dupixent® in the European Union to treat severe atopic dermatitis in children aged 6 months to 5 years old who are candidates for systemic therapy.

• Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

  3/18/2023

  Positive results from the clinical trial assessing Dupixent® in adults and adolescents with uncontrolled moderate-to-severe atopic hand and foot dermatitis were presented.

• Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis

  3/18/2023

  Regeneron Pharmaceuticals, Inc. and Sanofi presented positive results from the clinical trial assessing Dupixent® in adults and adolescents with uncontrolled moderate-to-severe atopic hand and foot dermatitis.

• Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance

  3/16/2023

  Sanofi announces that it will cut the list price of Lantus 100 Units/mL, its most widely prescribed insulin in the U.S., by 78 percent.

• 

  Sanofi Bolsters Diabetes Position with $2.9B Provention Buyout

  3/13/2023

  Sanofi will acquire diabetes leader Provention Bio for $25 per share for a total of $2.9 billion, the companies announced Monday. 

• Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review

  3/7/2023

  Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration has accepted for review the supplemental Biologics License Application for Dupixent® to treat adults and adolescents aged 12 years and older with chronic spontaneous urticaria that is not adequately controlled with the current standard of care, H1 antihistamine treatment.

• Positive topline results from pivotal XTEND-Kids phase 3 study of efanesoctocog alfa in children under 12 years of age with haemophilia A: Swedish Orphan Biovitrum AB

  3/2/2023

  Sobi® and Sanofi announced that the XTEND-Kids phase 3 pivotal study evaluating the safety, efficacy and pharmacokinetics of efanesoctocog alfa as once-weekly prophylaxis in previously treated patients under 12 years of age with severe haemophilia A met its primary endpoint.

• Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children <12 years of age with hemophilia A

  3/2/2023

  The XTEND-Kids phase 3 pivotal study evaluating the safety, efficacy and pharmacokinetics of ALTUVIIIO as once-weekly prophylaxis in previously treated patients <12 years of age with severe hemophilia A met its primary endpoint of safety, with no FVIII inhibitors detected in 74 children, with more than 50 children experiencing at least 50 exposure days, nearly a full year of treatment.

• 

  Sanofi R&D Head Steps Down Ahead of Busy 2023 Schedule

  2/13/2023

  Sanofi’s global head of R&D, John Reed, is leaving his position to pursue another opportunity outside the company, the French multinational announced Monday.

• Press Release: Sanofi announces change in R&D leadership

  2/13/2023

  Paris, February 13, 2023. Sanofi announced that Dr. John Reed, its Global Head of R&D, will be leaving the company to pursue a new opportunity outside Sanofi.

• Press Release : Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone

  2/3/2023

  Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone

• Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers

  1/25/2023

  Innate Pharma SA announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the previously announced expansion of its collaboration with Sanofi.

• Press Release: NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A

  1/25/2023

  Pivotal study data published in The New England Journal of Medicine continues to highlight the efficacy, safety, and pharmacokinetic profile of efanesoctocog alfa, an investigational treatment for hemophilia A.

• 

  Sanofi and CytoReason Target IBD in Expanded Collaboration (Updated)

  1/23/2023

  Sanofi licensed CytoReason's inflammatory bowel disease model in a multi-million dollar bid to identify new therapies for IBD and Crohn’s and colitis.

• CytoReason to License Its IBD Disease Model to Sanofi in Expanded Multiyear, Multimillion Dollar Deal

  1/23/2023

  CytoReason, a leader and pioneer in computational disease modeling, announced an expansion of its collaboration with Sanofi.

• Press Release: Sanofi Ventures announces multi-year capital commitment from Sanofi, increasing evergreen fund to $750M

  1/11/2023

  Paris, January 11,2023 Sanofi Ventures has announced an additional multi-year commitment from Sanofi, with an increase in capital to more than $750 million to the evergreen venture fund.

• NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs

  1/10/2023

  NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.

• Press Release: FDA accepts nirsevimab application as first protective option against RSV disease for all infants

  1/5/2023

  The U.S. Food and Drug Administration Center for Drug Evaluation and Research has accepted the Biologics License Application for nirsevimab for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants entering or during their first RSV season and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

• Press Release: Availability of the Q4 2022 Memorandum for modelling purposes

  1/4/2023

  Sanofi announced that its Q4 2022 Memorandum for modelling purposes is available on the "Investors" page of the company's website: